Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NXY-059 · 3 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| NXY-059 | DRUG | - |
Inclusion Criteria: * Males and females * Acute ischemic stroke with limb weakness, onset of symptoms within 6 hours * Full functional independence prior to the present stroke Exclusion Criteria: * Unconsciousness * Subjects who are unlikely to complete the infusion of investigational product and...
NXY-059 is an investigational small molecule being developed for cerebral stroke and intracerebral hemorrhage. It has been studied in patients who have suffered a stroke, including acute ischemic stroke and transient ischemic attack. The drug is in Phase 3 clinical development but is not approved by the FDA.
NXY-059 is a free radical trapping agent, also known as a nitrone, that is designed to protect the brain from damage after a stroke. It works by trapping free radicals that are generated during ischemia and reperfusion, thereby reducing oxidative stress and neuronal injury.
NXY-059 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca has conducted clinical trials to evaluate the safety and effectiveness of NXY-059 in stroke patients.
NXY-059 is in Phase 3 clinical development. It has completed two Phase 3 trials and one Phase 2 trial, with a total enrollment of approximately 4,900 patients. However, it remains investigational and has not received FDA approval.
NXY-059 has been studied in three completed clinical trials. NCT00061022 was a Phase 3 trial with 3,200 patients for cerebral stroke. NCT00075959 was a Phase 2 trial with 600 patients for intracerebral hemorrhage. NCT00119626 was a Phase 3 trial with 1,700 patients for cerebral stroke.
NXY-059 is also known as cerovive, a name that was used in earlier research and development. The drug is a nitrone-based free radical scavenger developed by AstraZeneca for the treatment of stroke. Both names refer to the same investigational compound.